The Phase 3 placebo-controlled CAPltello-291 trial reported an improvement in progression-free survival with the addition of the AKT inhibitor, capivasertib to fulvestrant in patients with ER+ advanced breast cancer, irrespective of PIK3CA mutation status [97]. Here, AKT1 is linked to breast cancer.